Uncategorized

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called bluebird bio? We wanted to know too.

Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

Matthew Galeotti, head of the justice department’s criminal division, called the operation “the beginning of a new era of aggressive prosecution and data driven prevention” of healthcare fraud.

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the FDA’s first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, senior director, pv systems and innovations at IQVIA.

After a marathon “vote-a-rama,” the Senate narrowly passed the legislation 51-50, with Vice President JD Vance casting the tiebreaking vote.

The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including insulin patch pumps. Here’s a roundup of MedTech Dive’s coverage.

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been attached to approved CAR T cancer therapies reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”

Beginning next year, the CMS will launch an AI-powered prior authorization process for some services as it seeks to cut funding for what it deems medically unnecessary care.

Experts speaking at the ADA’s Scientific Sessions supported making CGMs more accessible, but debated their usefulness for adults without diabetes.

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small molecule drugs.